LastMile – improving through digital LastMile – improving through digital LastMile initiative is an integrated, solutions-driven program seeking to make animal medical resources available in hard-to-reach areas in Africa.
Boehringer Ingelheim acquires Global Stem cell Technology Boehringer Ingelheim acquires Global Stem cell Technology Boehringer Ingelheim acquires Global Stem cell Technology, Belgian veterinary biotech company, to strengthen its stem cell capabilities in Animal Health
Trailr2-cdh17-antibody-phase1-trial Trailr2-cdh17-antibody-phase1-trial Boehringer Ingelheim advances a bi-specific therapeutic antibody to first-in-human clinical trial for patients with advanced gastrointestinal cancers
inauguration_biopharmaceutical_production_facility_vienna inauguration_biopharmaceutical_production_facility_vienna The state-of-the-art biopharmaceutical production facility in Vienna is the single largest investment in the company's history.
New Therapeutic Antibody Discovery Collaboration New Therapeutic Antibody Discovery Collaboration Proprietary antibody libraries to help discover therapeutic antibodies against multiple targets
ArisGlobal acquires Boehringer Ingelheim technology ArisGlobal acquires Boehringer Ingelheim technology Boehringer Ingelheim’s signal analytics technology is acquired by ArisGlobal
Boehringer Ingelheim announces collaboration with MabGenesis Boehringer Ingelheim announces collaboration with MabGenesis Boehringer Ingelheim announces collaboration with MabGenesis to discover and develop novel monoclonal antibodies in canine
Monoclonal antibodies Boehringer Ingelheim and Invetx Monoclonal antibodies Boehringer Ingelheim and Invetx Boehringer Ingelheim and Invetx announce collaboration to discover, develop and commercialize novel veterinary monoclonal antibody biotherapeutics
Inauguration of new global center for veterinary vaccine R&D Inauguration of new global center for veterinary vaccine R&D Inauguration of a new global hi-tech centre for biological research and development in Lyon.
IL-11 inhibitor antibody clinical development launched IL-11 inhibitor antibody clinical development launched Boehringer Ingelheim has launched clinical development of its first-in-class IL-11 inhibitor antibody as a fibrotic disease treatment
Advancing health equity for rural doctors in Mexico Advancing health equity for rural doctors in Mexico Our virtual sales team helps doctors stay informed through digital education about the latest treatments, regardless of their location
Retinal Health: Meet the Scientists Retinal Health: Meet the Scientists We aim to prevent, treat, and restore vision loss. Delve behind the lab to see our scientists spearheading research to address retinopathies.
Partnership Boehringer Ingelheim Lifebit health data Partnership Boehringer Ingelheim Lifebit health data Boehringer Ingelheim and Lifebit announce partnership to capture transformational value of health data
Global language learning platform for our people Global language learning platform for our people One global learning platform for languages, countless opportunities to grow your career
Outside the lab…inside the family Outside the lab…inside the family We are a manufacturing and a research company too. Outside of the lab, we have engineers, legal teams, logistics managers, QA/QC teams and more.
2019 performance 2019 performance Global Support Program addresses COVID-19 crisis with relief fund initiatives and volunteering support, donations, and concrete research activities.
collaboration-Yale collaboration-Yale Yale-Boehringer Ingelheim Biomedical Data Science Fellowship Program Seeks to Attract Top Researchers from Around the World
Rabies prevention local action partnering organizations Rabies prevention local action partnering organizations Global rabies prevention needs local action. Together with partnering organizations, we’re using pilot projects to find the right approach.
License deal with A*STAR to develop cancer antibodies License deal with A*STAR to develop cancer antibodies License deal with A*STAR to develop cancer antibodies